180 related articles for article (PubMed ID: 36439485)
1. Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis.
Chen LR; Li YJ; Zhang Z; Wang P; Zhou T; Qian K; Fan YX; Guo Y; He GH; Shen L
Front Oncol; 2022; 12():924208. PubMed ID: 36439485
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
[TBL] [Abstract][Full Text] [Related]
3. Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis.
Lei W; Xie M; Jiang Q; Xu N; Li P; Liang A; Young KH; Qian W
Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359816
[TBL] [Abstract][Full Text] [Related]
4. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
[TBL] [Abstract][Full Text] [Related]
5. An Analysis of Cardiac Disorders Associated With Chimeric Antigen Receptor T Cell Therapy in 126 Patients: A Single-Centre Retrospective Study.
Qi K; Yan Z; Cheng H; Chen W; Wang Y; Wang X; Cao J; Zhang H; Sang W; Zhu F; Sun H; Li D; Wu Q; Qiao J; Fu C; Zeng L; Li Z; Zheng J; Xu K
Front Oncol; 2021; 11():691064. PubMed ID: 34195092
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety-A Systematic Review with Meta-Analysis.
Yu WL; Hua ZC
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30621018
[TBL] [Abstract][Full Text] [Related]
7. Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy: a meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy.
Bindal P; Patell R; Chiasakul T; Lauw MN; Ko A; Wang TF; Zwicker JI
J Thromb Haemost; 2024 Apr; ():. PubMed ID: 38574863
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
9. Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias.
Simbaqueba CC; Aponte MP; Kim P; Deswal A; Palaskas NL; Iliescu C; Jahangir E; Yang EH; Steiner RE; Lopez-Mattei J
J Immunother Precis Oncol; 2020 Aug; 3(3):113-120. PubMed ID: 35663258
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy in the treatment of relapsed and refractory multiple myeloma: a systematic-review and meta-analysis of clinical trials.
Li J; Tang Y; Huang Z
Transl Cancer Res; 2022 Mar; 11(3):569-579. PubMed ID: 35402175
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.
Totzeck M; Michel L; Lin Y; Herrmann J; Rassaf T
Eur Heart J; 2022 May; 43(20):1928-1940. PubMed ID: 35257157
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis.
Jang JK; Pyo J; Suh CH; Park HS; Chae YK; Kim KW
Front Oncol; 2022; 12():851877. PubMed ID: 35692797
[TBL] [Abstract][Full Text] [Related]
14. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
15. Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis.
Cao G; Lei L; Zhu X
Medicine (Baltimore); 2019 Oct; 98(42):e17506. PubMed ID: 31626107
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.
Chen W; Wang Y; Qi K; Shi M; Cao J; Bhansali R; Wang X; Liu Y; Li H; Zhang H; Yan Z; Sang W; Cheng H; Zhu F; Sun H; Li D; Jing G; Zheng J; Li Z; Xu K
Transplant Cell Ther; 2021 Mar; 27(3):273.e1-273.e5. PubMed ID: 33781540
[TBL] [Abstract][Full Text] [Related]
17. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review.
Hanna KS; Kaur H; Alazzeh MS; Thandavaram A; Channar A; Purohit A; Shrestha B; Patel D; Shah H; Mohammed L
Cureus; 2022 Aug; 14(8):e28162. PubMed ID: 36148204
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular disease and chimeric antigen receptor cellular therapy.
Rao A; Stewart A; Eljalby M; Ramakrishnan P; Anderson LD; Awan FT; Chandra A; Vallabhaneni S; Zhang K; Zaha VG
Front Cardiovasc Med; 2022; 9():932347. PubMed ID: 36211558
[TBL] [Abstract][Full Text] [Related]
20. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
